10-year survival in patients diagnosed with high-grade epithelial ovarian cancer: a new metric for a new millennium
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)00781-2
Abstract: Objectives: To determine 10-year (yr) overall survival (OS) for patients (pts) diagnosed with high-grade epithelial ovarian cancer (HGEOC). Methods: We analyzed the records of all pts diagnosed with HGEOC who underwent primary treatment at our… read more here.
Keywords: grade; high grade; diagnosed high; survival patients ... See more keywords
Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1744613
Abstract: Abstract Aims: Treatment of acute myeloid leukemia (AML) requires significant healthcare resource utilization (HRU), including lengthy hospitalizations. In a phase 3 study (NCT01696084), CPX-351 (Vyxeos) showed significant benefits to overall survival and complete remission versus… read more here.
Keywords: newly diagnosed; high risk; study; diagnosed high ... See more keywords
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003510
Abstract: CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine in a synergistic 1:5 molar ratio, is approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). In… read more here.
Keywords: newly diagnosed; cpx; adults newly; diagnosed high ... See more keywords